Canon Inc.
2023 Corporate Strategy Conference

Medical Group

March 6, 2023

Toshio Takiguchi

Senior Managing Executive Officer


Head of Medical Group

Canon

This presentation contains forward-looking statements with respect to future results, performance and achievements that are subject to risk and uncertainties and reflect management's views and assumptions formed by available information. All statements other than statements of historical fact are statements that could be considered forward-looking statements. When used in this document, words such as "anticipate," "estimate," "expect," "intend," "may," "plan," "project" or "should" and similar expressions, as they relate to Canon, are intended to identify forward-looking statements. Many factors could cause the actual results, performance or achievements of Canon to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, among others, changes in general economic and business conditions, changes in currency exchange rates and interest rates, introduction of competing products by other companies, lack of acceptance of new products or services by Canon's According to the currency exchange rates and interest rates, introduction of competing products by other companies, lack of acceptance of new products or services by Canon's According to the currency exchange rates and interest rates, introduction of competing products by other companies, lack of acceptance of new products or services by Canon's annual report on Form 20-F, which is on file with the United States Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein. Canon does not intend or assume any obligation to update these forward-looking statements.

5-year Plan Group Net Sales





Growth Strategy



Basic Policy 2020 to 2022 – Focus on strengthening internal structure to raise organizational strength and grow top line from 2023

2020 **Stage 1** 2022

Prepare growth engines




Strengthen product competitiveness

- Offer new value through development of next-generation technologies with diagnostic imaging at its core
- Strengthen and expand in-vitro diagnostics and healthcare IT business portfolio



- Strengthen sales structure in U.S. and raise presence
- CRM-based sales productivity enhancement



- · Promote efficiency incorporating DX
- Change manufacturing structure

2023 **Stage 2** 2025

Realize growth through strengthened structure and prepared growth engines

Aim for annual sales growth of 5% or more

- Global No. 1 share of CT market
- Achieve 10% or more mkt. shr. in U.S.
- Deploy U.S. presence globally
- Achieve overwhelming No. 1 position in Japan
- Maximize profit through increased sales

Achieve op. profit ratio of 10% or more



Major Activities – 2022 (Prepare growth engines)



Strengthen product competitiveness

Business contribution

Realized MRI system manufactured solely by Canon









Cost

- Early commercialization of X-ray CT System with Photon-counting Detector
 - Acquired Redlen Technologies
 - Started joint research with Japan National Cancer Research Center



New value

Improved workflow through Canon camera technology and ΑI





Strengthened X-ray product lineup through acquisition of NRT



Cost






■Strengthen sales capability

- Strengthen sales capability in U.S.
 - Strategy to strengthen U.S. territories
- Change U.S. sales commission system
- Acquired/integrate NXC



CMCU/CMCE establish

- Commercially integrate Canon Inc. & CETD products
- Capture global account bus., eliminating territory resale
- **Restructure health care IT business**
 - Strengthen structure as a Canon Group



*CMI: Canon Medical Informatics, Inc. *RSS: Reading Support Solution

'TOS: Electronic medical records and medical accounting systems for clinics

*SI of HIS: System integration of hospital information

- Strengthen business constitution and structure
- **Return to production system centered in Japan**
- Closed Canon Medical Malaysia plant





- **Constructed new electron tube factory** building
- Strengthen cost competitiveness through automation
- Setup labor saving production line



- **Newly established testing center**
- Anechoic chamber and large/medium thermostatic chamber enabling public testing



Major Achievements in 2022



Record-high sales and profit for the Medical Group


Net sales: 513.3 billion yen
 Operating profit: 31.0 billion yen

■8 consecutive periods of Y/Y sales growth in U.S. market

 Recorded 8 consecutive quarters of sales growth up to and including 2Q 2022

■Captured No. 1 share of MRI market in Japan

- Realized improved workflow through adoption of Canon camera technology
- Acquired 30% or more share of 1.5 T market in Japan





Major Measures of 2023



Phase VI Basic Policy 2020 to 2022 – Focus on strengthening internal structure to raise organizational strength and grow top line from 2023

→ Realize growth through strengthened structure and prepared growth engines

Strengthen product competitiveness

Early commercialization of PCCT

- Propose new clinical value
- Capture No. 1 share of global CT market



Offer clinical value through AI technology

- Low-dose radiation high-resolution technology (AiCE)
- Super-resolution deep-learning reconstruction technology (PIQE)






■Strengthen sales capability

Strengthen sales capability in U.S.

- Canon Healthcare USA, INC. est.
- Raise presence in U.S.
- Strengthen competitiveness globally



Strengthen sales structure in India and Middle East

- New company established in India as of January 2023
- Also have plans to expand business sites in Saudi Arabia and UAE



Strengthen business constitution and structure

Raise gross profit

Lower costs

- Transform manufacturing structure
- Establish the Product Value Engineering Promotion Division



Improve productivity

- Standardized Sales operation based on CRM
- Increase in sales per person



Early Realization of Signature Canon PCCT



- Acquired Canada-based Redlen Technologies in 2021, developing and manufacturing semiconductor-based detector modules
- Utilizing Redlen's technology, developed Japan's first X-ray CT equipped with photon counting detector
- Japan's National Cancer Center completed installation at Advanced Medical Development Center and began Clinical evaluation

Future moves to commercialize

Start joint research with medical institutions in the U.S.

Combine KOL strategy with measures aimed at raising PCCT clinical value

Early realization of PCCT that has new clinical value



Establishment of New Company in U.S.



1.	Co. Name	Canon Healthcare USA, INC.
2.	Location	Ohio, USA
3.	Directors	Chairman: Hiroyuki Fujita President: Hisashi Tachizaki
4.	Business profile	Marketing activities through cooperation with medical institutions
5.	Foundation	February 1 2023
6.	Investment ratio	Canon Inc. (100%)
7.	No. of employees	20 (Plan)



Strengthen marketing activities

X Strengthen customer alignment

Strengthen business structure



Strengthen global competitiveness by raising presence in U.S.

Activities to Accelerate Cost Reduction



With the aim of transforming manufacturing structure, establish Product Value Engineering and Planning Group. Promote concurrent engineering and control of internal and external production of units.

Reduce all costs: Further raise production efficiency in manufacturing process, improve yield rates, eliminate need for rework

Create unified development design and manufacturing site
Realize manufacturing through best production processes from a quality perspective



Accelerate cost reduction of key components used in Canon's medical equipment



Laterally deploy successes of Canon Toride Plant



Expand Business Area by Contribution to Precision Medicine



Current business areas

Test & Diagnosis

Business area expansion

Solutions that support personalized therapy

Realize Clinical Decision

Support

Specimen testing Figure 1. The second secon

Pathological diagnosis

Liquid biopsy

Genetic testing

Regenerative medicine

Medical support system Integrate

Collect & integrate Process & distribute RSS

SS Next-generation

Easier, quicker, and cleaner for everyone

Morphological diagnosis

CT: Ultra-high

definition chest image

Dynamic diagnosis

CT: Cardiac dynamic

imaging

Functional diagnosis

MR: Cranial nerve image

Development axis

diagnostic imaging equipment



Standing CT



Big data analysis

Cloud platform

Remote diagnostic support

autologous iPS cell production

Regenerative medicine platform



<u>Individualized</u> treatment

- Medical treatment
- Surgical treatment
- Cell therapy
- Regenerative medicine

Diagnostic imaging & Health care IT

In-Vitro & Bio